Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Daiichi Sankyo
Cipla
Cerilliant
AstraZeneca
Moodys
Covington
Chubb
Fuji

Generated: April 26, 2018

DrugPatentWatch Database Preview

HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE Drug Profile

« Back to Dashboard

Which patents cover Hydrochlorothiazide W/ Reserpine And Hydralazine, and when can generic versions of Hydrochlorothiazide W/ Reserpine And Hydralazine launch?

Hydrochlorothiazide W/ Reserpine And Hydralazine is a drug marketed by Watson Labs and is included in one NDA.

The generic ingredient in HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.
Summary for HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE
Drug patent expirations by year for HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Watson Labs HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE hydralazine hydrochloride; hydrochlorothiazide; reserpine TABLET;ORAL 083770-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Fuji
Boehringer Ingelheim
US Department of Justice
Cipla
Fish and Richardson
QuintilesIMS
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.